Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) today announced the successful completion of an extensive reorganization of its business, code-named ‘Project Manifest’. This reorganization is a significant milestone, positioning the company for enhanced operational efficiency and growth by:
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) announced today its Board of Directors has approved a distribution payment of $0.35 per common share to be paid on December 31, 2024 to all shareholders of record as of the close of business on December 24, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (the “Company”) today reported an increase of 77% in net income available to shareholders to $33.9 million or $2.48 per share for the nine months ended September 30, 2024 compared to $19.2 million or $1.39 per share for the same period in 2023.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”), announced today that it will release its third quarter 2024 earnings before market open on Thursday, November 7, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) announced today its Board of Directors has approved a distribution payment of $0.35 per common share to be paid on October 7, 2024 to all shareholders of record as of the close of business on September 30, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (the “Company”) today reported an increase of 83% in net income available to shareholders to $21.2 million or $1.55 per share for the six months ended June 30, 2024 compared to $11.6 million or $0.84 per share for the same period in 2023.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”), announced today that it will release its second quarter 2024 earnings before market open on Wednesday, August 7, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) announced today its Board of Directors has approved a distribution payment of $0.35 per common share to be paid on June 28, 2024 to all shareholders of record as of the close of business on June 21, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (the “Company”) today reported net income available to shareholders of $11.3 million for the three months ended March 31, 2024 compared to $2.4 million for the same period in 2023.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”), announced today that it will release its first quarter 2024 earnings before market open on Wednesday, May 8, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (the “Company”) today reported net income available to shareholders for the twelve months ended December 31, 2023, of $25.0 million compared to net loss available to shareholders of $1.3 million for the corresponding period in 2022. Adjusted operating income per share was $1.96 in 2023, an increase of 125% over $0.87 in 2022, driven by a 95.2% accident year combined ratio in the Company’s Penn-America excess and surplus lines insurance business and $55.4 million of net investment income, which increased 101% over 2022. The Company also reduced gross written premium of its Non-Core Operations by 86%. Book value per share increased 8.2% (including $1.00 per share of dividends paid during 2023) to $47.53 at December 31, 2023.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQSGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) announced today that its Board of Directors approved a dividend rate of $0.35 per common share payable on March 28, 2024 to all shareholders of record as of the close of business on March 21, 2024, a 40% increase over the prior quarterly dividend rate of $0.25 per common share.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”), announced today that it will release its 2023 earnings before market open on Wednesday, March 13, 2024.
Global Indemnity Group, LLC (NYSEGBLI) (“GBLI”) announced today its Board of Directors has approved a distribution payment of $0.25 per common share to be paid on December 29, 2023 to all shareholders of record as of the close of business on December 22, 2023.
Global Indemnity Group, LLC (NYSEGBLI) (“Global Indemnity” or the “Company”) announced today that it suspended the exploration of the sale or merger of Penn-America, Global Indemnity’s insurance group, and Global Indemnity itself at this time.
